Toshimitsu Hamasaki

Generating author description...

All published works

Action	Title	Year	Authors
+	Data Monitoring Committee Reports: Telling the Data’s Story	2024	Lijuan Zeng Toshimitsu Hamasaki Scott Evans
+	Longitudinal benefit:risk analysis through the desirability of outcome ranking (DOOR) with application to ACTT-1 Trial	2024	Shiyu Shu Guoqing Diao Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs	2024	Tori Kinamon Ursula Waack Mark Needles Daniel B. Rubin Deborah Collyar Sarah B. Doernberg Scott Evans Toshimitsu Hamasaki Thomas L Holland Jessica Howard‐Anderson
+	Design of Clinical Trials with the Desirability of Outcome Ranking Methodology	2024	Toshimitsu Hamasaki Yijie He Q Wu Scott Evans
+	Benefit:Risk Assessments During Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR)	2024	Lijuan Zeng Toshimitsu Hamasaki Lizhao Ge Yijie He Scott Evans
+	<i>Statistics in Biopharmaceutical Research</i> Best Papers Award 2023	2023	Toshimitsu Hamasaki Freda Cooner
+	Generalized fiducial inference for the restricted mean survival time	2023	Ionut Bebu Guoqing Diao Toshimitsu Hamasaki
+ PDF Chat	Editor’s Note: Special Section on a Collection of Articles on Opportunities and Challenges in Utilizing Real-World Data for Clinical Trials and Medical Product Development	2023	Toshimitsu Hamasaki
+ PDF Chat	Weighing evidence: robustness vs quantity	2022	Scott Evans Toshimitsu Hamasaki
+ PDF Chat	Statistics in Medicine	2022	Weixiao Dai Toshimitsu Hamasaki
+	[Multiple Endpoints in Oncology Clinical Trials].	2022	Toshimitsu Hamasaki Frank Bretz
+	Multiple Endpoints in Multiregional Clinical Trials	2021	Toshimitsu Hamasaki Yuh‐Jenn Wu Chin‐Fu Hsiao
+	Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics	2021	Freda Cooner Toshimitsu Hamasaki Frank Bretz Gene Pennello Martin Posch
+ PDF Chat	<i>Statistics in Biopharmaceutical Research</i> Best Papers Award	2021	Toshimitsu Hamasaki Frank Bretz
+ PDF Chat	Special Issue for Selected Articles From the ISBS2019: Statistical Innovation and Contribution in the Era of Precision Healthcare	2021	Toshimitsu Hamasaki Satoshi Morita Jie Chen
+ PDF Chat	Editorial: Roles of Hypothesis Testing, <i>p</i>-Values and Decision Making in Biopharmaceutical Research	2021	Toshimitsu Hamasaki Frank Bretz Lisa M. LaVange Peter Müller Gene Pennello José Cirı́aco Pinheiro
+	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes	2020	Toshimitsu Hamasaki Hung Hung Chin‐Fu Hsiao Scott Evans
+ PDF Chat	Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic	2020	Toshimitsu Hamasaki Frank Bretz Freda Cooner Lisa M. LaVange Martin Posch
+	Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations	2020	Xiaoyan Yin Toshimitsu Hamasaki Scott Evans
+ PDF Chat	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design	2020	Munyaradzi Dimairo Philip Pallmann James Wason Susan Todd Thomas Jaki Steven A. Julious Adrian Mander Christopher J. Weir Franz Koenig Marc K. Walton
+ PDF Chat	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design	2020	Munyaradzi Dimairo Philip Pallmann James Wason Susan Todd Thomas Jaki Steven A. Julious Adrian Mander Christopher J. Weir Franz Koenig Marc K. Walton
+	Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations	2020	X. Y. Yin Toshimitsu Hamasaki Scott Evans
+	Analysis of ordered composite endpoints	2019	Dean Follmann Michael P. Fay Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction	2019	Koko Asakura Scott Evans Toshimitsu Hamasaki
+ PDF Chat	The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design	2019	Munyaradzi Dimairo Philip Pallmann James Wason Susan Todd Thomas Jaki Steven A. Julious Adrian Mander Christopher J. Weir Franz Koenig Marc K. Walton
+	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes	2019	Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans Susan Halabi
+	Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction	2019	Koko Asakura Scott Evans Toshimitsu Hamasaki
+	Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction	2019	Koko Asakura Scott Evans Toshimitsu Hamasaki
+ PDF Chat	Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)	2019	Evans S.R. Dean Follmann Liu Y Thomas L Holland Doernberg S.B. Nadine Rouphael Toshimitsu Hamasaki Yunyun Jiang Lok J. Tran T.T.T.
+ PDF Chat	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design	2018	Munyaradzi Dimairo Elizabeth Coates Philip Pallmann Susan Todd Steven A. Julious Thomas Jaki James Wason Adrian Mander Christopher J. Weir Franz Koenig
+ PDF Chat	Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)	2018	Scott Evans Dean Follmann Ying Liu Thomas L Holland Sarah B. Doernberg Nadine Rouphael Toshimitsu Hamasaki Yunyun Jiang Judith J. Lok Thuy Tien T. Tran
+ PDF Chat	Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review	2017	Toshimitsu Hamasaki Scott Evans Koko Asakura
+ PDF Chat	Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints	2017	Wong-Shian Huang H. M. James Hung Toshimitsu Hamasaki Chin‐Fu Hsiao
+ PDF Chat	Sizing clinical trials when comparing bivariate time‐to‐event outcomes	2017	Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans Takashi Sozu
+ PDF Chat	Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints	2016	Koko Asakura Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Corrigendum: A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints (10.1093/biostatistics/kxs057)	2016	Tomoyuki Sugimoto Takashi Sozu Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Group-sequential three-arm noninferiority clinical trial designs	2016	Toshimitsu Ochiai Toshimitsu Hamasaki Scott Evans Koko Asakura Yuko Ohno
+	Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Sample Size Recalculation in Clinical Trials with Two Co-primary Endpoints	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Group-Sequential Three-Arm Non-inferiority Clinical Trials	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Interim Evaluation of Efficacy or Futility in Clinical Trials with Two Co-primary Endpoints	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Interim Evaluation of Efficacy in Clinical Trials with Two Co-primary Endpoints	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Group-Sequential Clinical Trials with Multiple Co-Objectives	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Introduction	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Future Developments	2016	Toshimitsu Hamasaki Koko Asakura Scott Evans Toshimitsu Ochiai
+	Reducing unnecessary measurements in clinical trials with multiple primary endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki
+ PDF Chat	Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts	2015	Yukio Ando Toshimitsu Hamasaki Scott Evans Koko Asakura Tomoyuki Sugimoto Takashi Sozu Yuko Ohno
+ PDF Chat	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes	2015	Toshimitsu Hamasaki Koko Asakura Scott Evans Tomoyuki Sugimoto Takashi Sozu
+	Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpoints	2015	Koko Asakura Toshimitsu Hamasaki Scott Evans Tomoyuki Sugimoto Takashi Sozu
+	Sample Size Determination in Clinical Trials with Multiple Endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Convenient Sample Size Formula	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Binary Co-primary Endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Continuous Co-primary Endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Two-sample tests for comparing proportions	2015	Koko Asakura Toshimitsu Hamasaki
+ PDF Chat	Multiple comparisons: comparing more than two treatments	2015	Koko Asakura Toshimitsu Hamasaki
+ PDF Chat	Two-sample tests for comparing means	2015	Koko Asakura Toshimitsu Hamasaki
+ PDF Chat	Analysis of survival data	2015	Koko Asakura Toshimitsu Hamasaki
+	Introduction	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Continuous Primary Endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Further Developments	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans
+	Design Challenges for Heart Failure Prevention Clinical Trials: Adaptive Design Approach	2014	Toshimitsu Hamasaki Atsushi Nakano Kanae Takahashi Hideaki Kanzaki Masanori Asakura Masafumi Kitakaze
+ PDF Chat	Sample size determination in group‐sequential clinical trials with two co‐primary endpoints	2014	Koko Asakura Toshimitsu Hamasaki Tomoyuki Sugimoto Kenichi Hayashi Scott Evans Takashi Sozu
+ PDF Chat	Partition testing in confirmatory adaptive designs with structured objectives	2013	Toshifumi Sugitani Toshimitsu Hamasaki Chikuma Hamada
+ PDF Chat	A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints	2013	Tomoyuki Sugimoto Takashi Sozu Toshimitsu Hamasaki Scott Evans
+ PDF Chat	Statistical Issues in Clinical Trials with Multiple Primary Endpoints	2013	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki
+ PDF Chat	Sample size determination for clinical trials with co‐primary outcomes: exponential event times	2012	Toshimitsu Hamasaki Tomoyuki Sugimoto Scott Evans Takashi Sozu
+	Sample size determination in clinical trials with multiple co‐primary endpoints including mixed continuous and binary variables	2012	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki
+	A convenient formula for sample size calculations in clinical trials with multiple co‐primary continuous endpoints	2012	Tomoyuki Sugimoto Takashi Sozu Toshimitsu Hamasaki
+	Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints	2011	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki
+ PDF Chat	A simple modification of the Box and Cox transformation to scale stability and invariance	2011	Toshimitsu Hamasaki Tomoyuki Sugimoto Seoyoung C. Kim
+	A Note on Analysis of Ratio of Two Correlated Normal Variables	2011	Koko Asakura Hiroyuki Uesaka Tomoyuki Sugimoto Toshimitsu Hamasaki
+	Sample size determination in clinical trials with multiple co‐primary binary endpoints	2010	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki
+	Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective	2010	Yukio Ando Toshimitsu Hamasaki
+ PDF Chat	Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder	2010	Ichiro Arano Tomoyuki Sugimoto Toshimitsu Hamasaki Yuko Ohno
+ PDF Chat	Box and Cox power-transformation to additivity and homoscedasticity in regression	2010	Toshimitsu Hamasaki Tomoyuki Sugimoto Masashi Goto
+ PDF Chat	A COMPARISON OF METHODS FOR PARAMETER ESTIMATION OF THE SHIFTED POWER TRANSFORMATION	2007	Toshimitsu Hamasaki Tomoyuki Sugimoto
+ PDF Chat	The Role of Randomization in Clinical Trials	2007	Ichiro Arano Toshimitsu Hamasaki Tomoyuki Sugimoto
+	Box and Cox power-transformation to confined and censored nonnormal responses in regression	2006	Toshimitsu Hamasaki Seoyoung C. Kim
+	Properties of estimators of baseline hazard functions in a semiparametric cure model	2006	Tomoyuki Sugimoto Toshimitsu Hamasaki
+ PDF Chat	Power-Transformation Model to Additivity in Regression	2005	Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	ASYMPTOTIC PROPERTIES OF ESTIMATES OF THE POWER-TRANSFORMATION MODEL TO BIVARIATE GROUPED DATA	2005	Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	DIAGNOSTIC METHODS IN THE APT MODEL FOR ORDERED CATEGORICAL DATA	2003	Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	SIMULTANEOUS DIAGNOSTIC METHODS FOR THE DOUBLE POWER-NORMAL TRANSFORMATION MODEL	2003	Masashi Goto Toshimitsu Hamasaki
+ PDF Chat	2. Clinical and Medical Evaluation Process	2003	Tatsuya Isomura Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	STATISTICAL INFERENCES OF GROUPED DATA COMBINED WITH UNGROUPED DATA FROM THE POWER-NORMAL DISTRIBUTION	2002	Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	On Inferences of Parameters in the Bivariate Power-Normal Distribution	2002	Toshimitsu Hamasaki Masashi Goto
+	PRACTICAL ISSUES AND OBSERVATIONS ON THE USE OF FOREIGN CLINICAL DATA IN DRUG DEVELOPMENT	2002	Masashi Goto Toshimitsu Hamasaki
+	Statistical Approaches to Detecting Dose-Response Relationships	2000	Toshimitsu Hamasaki Tatsuya Isomura Mitsumasa Baba Masashi Goto
+ PDF Chat	None	1999	Toshimitsu Hamasaki Tatsuya Isomura Megu Ohtaki Masashi Goto
+ PDF Chat	INFERENCES BASED ON THE GROUPED OBSERVATIONS FROM THE BIVARIATE POWER-NORMAL DISTRIBUTION	1998	Toshimitsu Hamasaki Masashi Goto
+ PDF Chat	None	1998	Toshimitsu Hamasaki Masashi Goto
+	An Optimal Excitation Method in Multi-Applicator Systems for Forming a Hot Zone Inside the Human Body	1986	N. Morita Toshimitsu Hamasaki Naoya Kumagai

Common Coauthors

Coauthor	Papers Together
Scott Evans	40
Tomoyuki Sugimoto	29
Koko Asakura	23
Takashi Sozu	21
Masashi Goto	13
Toshimitsu Ochiai	9
Yukio Ando	6
Frank Bretz	5
Thomas Jaki	4
Susan Todd	4
Michael A. Proschan	4
Elizabeth Coates	4
Adrian Mander	4
Daniel Hind	4
Munyaradzi Dimairo	4
Marc K. Walton	4
Philip Pallmann	4
Jon Nicholl	4
Steven A. Julious	4
Christopher J. Weir	4
John Scott	4
James Wason	4
Katie Biggs	4
Douglas G. Altman	4
Franz Koenig	4
Henry F. Chambers	3
Freda Cooner	3
Yuko Ohno	3
Thomas L Holland	3
Dean Follmann	3
Chin‐Fu Hsiao	3
Helen W. Boucher	3
Tatsuya Isomura	3
Yijie He	2
Nadine Rouphael	2
X. Y. Yin	2
Lisa M. LaVange	2
Sarah B. Doernberg	2
Yunyun Jiang	2
Seoyoung C. Kim	2
Guoqing Diao	2
Lijuan Zeng	2
Vance G. Fowler	2
Gene Pennello	2
Ichiro Arano	2
Martin Posch	2
Olivier Collignon	1
Wong-Shian Huang	1
Hideaki Kanzaki	1
William J. Meurer	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Some Controversial Multiple Testing Problems in Regulatory Applications	2009	H. M. James Hung Sue-Jane Wang	22
+	A Multiple Testing Procedure for Clinical Trials	1979	Peter C. O’Brien Thomas R. Fleming	21
+ PDF Chat	Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America	2007	Walter Offen Christy Chuang‐Stein Alex Dmitrienko Gary S. Littman Jeff Maca Laura A. Meyerson Robb J. Muirhead Paul Stryszak Alex Baddy Kun Chen	20
+ PDF Chat	Sample size determination for clinical trials with co‐primary outcomes: exponential event times	2012	Toshimitsu Hamasaki Tomoyuki Sugimoto Scott Evans Takashi Sozu	18
+	A convenient formula for sample size calculations in clinical trials with multiple co‐primary continuous endpoints	2012	Tomoyuki Sugimoto Takashi Sozu Toshimitsu Hamasaki	18
+	Group sequential methods in the design and analysis of clinical trials	1977	Stuart J. Pocock	17
+	Sample size determination in clinical trials with multiple co‐primary binary endpoints	2010	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki	17
+	Discrete sequential boundaries for clinical trials	1983	K. K. Gordon Lan David L. DeMets	17
+	Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints	2011	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki	17
+	Challenge of multiple co‐primary endpoints: a new approach	2006	Christy Chuang‐Stein Paul Stryszak Alex Dmitrienko Walter Offen	16
+	Power and sample size when multiple endpoints are considered	2007	Stephen Senn Frank Bretz	15
+	Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial	2005	Chengjie Xiong Kai Yu Feng Gao Ying Yan Zhengjun Zhang	14
+ PDF Chat	A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints	2013	Tomoyuki Sugimoto Takashi Sozu Toshimitsu Hamasaki Scott Evans	14
+ PDF Chat	Sample size determination in group‐sequential clinical trials with two co‐primary endpoints	2014	Koko Asakura Toshimitsu Hamasaki Tomoyuki Sugimoto Kenichi Hayashi Scott Evans Takashi Sozu	13
+	Method of balanced adjustment in testing co‐primary endpoints	2010	George Kordzakhia Ohidul Siddiqui Mohammad F. Huque	13
+ PDF Chat	Power and Sample Size Calculations in Clinical Trials with Mutiple Primary Variables	2006	Takashi Sozu Takeshi Kanou Chikuma Hamada Isao Yoshimura	12
+	On a multiple endpoints testing problem	2007	Morris L. Eaton Robb J. Muirhead	12
+ PDF Chat	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes	2015	Toshimitsu Hamasaki Koko Asakura Scott Evans Tomoyuki Sugimoto Takashi Sozu	11
+	Modification of Sample Size in Group Sequential Clinical Trials	1999	Lu Cui H. M. James Hung Sue‐Jane Wang	10
+ PDF Chat	Multiple testing problems in pharmaceutical statistics	2011	Isaac Dialsingh	9
+	Discrete Sequential Boundaries for Clinical Trials	1983	K. K. Gordon Lan David L. DeMets	9
+	Power-normal distribution and its applications	1983	Masaki Goto	9
+ PDF Chat	Testing a Primary and a Secondary Endpoint in a Group Sequential Design	2010	Ajit C. Tamhane Cyrus R. Mehta Lingyun Liu	9
+	Multiple Testing Problems in Pharmaceutical Statistics	2009		9
+	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)	2015	Scott Evans Daniel B. Rubin Dean Follmann Gene Pennello W. Charles Huskins John H. Powers David Schoenfeld Christy Chuang‐Stein Sara E. Cosgrove Vance G. Fowler	8
+	Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints	2008	James Song	8
+	Hierarchical testing of multiple endpoints in group‐sequential trials	2009	Ekkehard Glimm Willi Maurer Frank Bretz	8
+	Sample size determination in clinical trials with multiple co‐primary endpoints including mixed continuous and binary variables	2012	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki	8
+	Correlated Binary Regression with Covariates Specific to Each Binary Observation	1988	Ross L. Prentice	8
+	Sample sizes for trials involving multiple correlated must‐win comparisons	2012	Steven A. Julious Nikki E. McIntyre	8
+	A Method for Generating High-Dimensional Multivariate Binary Variates	1991	Lawrence J. Emrich Marion R. Piedmonte	8
+ PDF Chat	Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints	1993	Christopher Jennison Bruce W. Turnbull	7
+	Numerical Computation of Multivariate Normal Probabilities	1992	Alan Genz	7
+	Sample Size Determination in Clinical Trials with Multiple Endpoints	2015	Takashi Sozu Tomoyuki Sugimoto Toshimitsu Hamasaki Scott Evans	7
+	A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence	1978	David Clayton	6
+	Stochastically curtailed tests in long–term clinical trials	1982	K. K. Gordon Lan Richard Simon Max Halperin	6
+	An Analysis of Transformations	1964	George E. P. Box David R. Cox	6
+ PDF Chat	Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials	2009	Lingling Li Scott Evans Hajime Uno L. J. Wei	6
+ PDF Chat	The Analysis of Transformed Data	1984	D. V. Hinkley George C. Runger	6
+	Statistical Monitoring of Clinical Trials With Multiple Co-Primary Endpoints Using Multivariate B-value	2014	Yansong Cheng Surajit Ray Mark Chang Sandeep Menon	6
+	An Analysis of Transformations Revisited	1981	Peter J. Bickel Kjell A. Doksum	6
+	Adaptive extensions of a two‐stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints	2012	Ajit C. Tamhane Yi Wu Cyrus R. Mehta	6
+	Multiple Comparisons Using R	2010	Frank Bretz Torsten Hothorn Peter H. Westfall	6
+	Adaptive Dunnett tests for treatment selection	2007	Franz Koenig Werner Brannath Frank Bretz Martin Posch	6
+	Group Sequential Methods with Applications to Clinical Trials	1999	Christopher Jennison Bruce W. Turnbull	6
+ PDF Chat	Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation	2016	Scott Evans Dean Follmann	6
+	A review of methods for futility stopping based on conditional power	2005	John M. Lachin	5
+	Procedures for Comparing Samples with Multiple Endpoints	1984	Peter C. O’Brien	5
+	Statistical Considerations for Testing Multiple Endpoints in Group Sequential or Adaptive Clinical Trials	2007	Hung Hung Sue‐Jane Wang Robert T. O’Neill	5
+	Estimating Significance Level and Power Comparisons for Testing Multiple Endpoints in Clinical Trials	2000	Jianjian Gong José Cirı́aco Pinheiro David L. DeMets	5